Patients with high GP73 expression were more likely to obtain less pathological tumor regression as compared to patients with low or no GP73 expression, these results indicate that GP73 correlates with the effect of neoadjuvant chemotherapy in advanced gastric cancer. Here, GOLM1 is linked to gastric cancer.